Last updated on August 2018

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients with Dementia, Including Alzheimer’s Disease

Brief description of study

To take part, your loved one must:

 be at least 55 years of age,

 be diagnosed with probable Alzheimer’s disease,

 be showing behaviors of agitation associated with Alzheimer’s,

 have a friend or loved one that can take part in the study with them.

Clinical Study Identifier: TX209898

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.